The post-consolidation standard of care therapies incorporates a combination of dinutuximab (a monoclonal antibody that targets the disialoganglioside (GD-2) (a glycolipid expressed on NB cells), cytokines (IL-2 and GM-CSF), and isotretinoin (a retinoid agent that induces differentiation of immature NB cells) [240]. This evidence concerns the gene CSF2 and neuroblastoma.